Heart Failure
Disease Education
Disease Education
Heart failure and CKD frequently coexist and share common risk factors, such as diabetes.2,3 There is a need to understand the challenges in these interconnected conditions.
Abbreviations
CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; UACR, urine albumin-to-creatinine ratio.
References
1. Kidney Disease Improving Global Outcomes. Kidney International. 2024;105(Suppl 4S):S117-S314. 2. Zannad F, Rossignol P. Circulation. 2018;138(9):929-944. 3. McCullough PA, et al. J Am Heart Assoc. 2022;11(11):e024139. 4. Bansal N, et al. J Am Coll Cardiol. 2019;73(21):2691-2700. 5. Paul SK, et al. Diabetes Care. 2022;45(8):1873-1881. 6. Damman K, et al. European Heart Journal. 2014;35(7):455-469. 7. Matsushita K, et al. Lancet Diabetes Endocrinol. 2015; 3(7):514-525.
Patients with heart failure and CKD, linked by common risk factors and mechanistic pathways, may experience substantial burden.2-4 Recognition of the consequences between these two diseases is needed to address cardiovascular-kidney-metabolic health.
Abbreviations
CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; UACR, urine albumin-to-creatinine ratio.
References
1. Kidney Disease Improving Global Outcomes. Kidney International. 2024;105(Suppl 4S):S117-S314. 2. Zannad F, Rossignol P. Circulation. 2018;138(9):929-944. 3. McCullough PA, et al. J Am Heart Assoc. 2022;11(11):e024139. 4. Bansal N, et al. J Am Coll Cardiol. 2019;73(21):2691-2700. 5. Paul SK, et al. Diabetes Care. 2022;45(8):1873-1881. 6. Damman K, et al. European Heart Journal. 2014;35(7):455-469. 7. Matsushita K, et al. Lancet Diabetes Endocrinol. 2015; 3(7):514-525.
View the videos below featuring leading cardiologists who are experts in CVD and HF.
Addressing Unmet Needs for
Patients With HFpEF
Dr. Biykem Bozkurt reviews the unmet needs and epidemiology of HFpEF and the limited treatment options.
Overview of the Pathophysiology of HF With LVEF ≥40%
Dr. Muthiah Vaduganathan discusses the pathophysiology of HF with LVEF ≥40% and the shared mechanisms of disease progression with CV and kidney diseases.
Exploring the Connection Between HF
and CKD
Dr. Javed Butler talks about the connection between heart and kidney diseases and the potential for common therapies to improve patient outcomes.
Abbreviations
CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; UACR, urine albumin-to-creatinine ratio.
References
1. Kidney Disease Improving Global Outcomes. Kidney International. 2024;105(Suppl 4S):S117-S314. 2. Zannad F, Rossignol P. Circulation. 2018;138(9):929-944. 3. McCullough PA, et al. J Am Heart Assoc. 2022;11(11):e024139. 4. Bansal N, et al. J Am Coll Cardiol. 2019;73(21):2691-2700. 5. Paul SK, et al. Diabetes Care. 2022;45(8):1873-1881. 6. Damman K, et al. European Heart Journal. 2014;35(7):455-469. 7. Matsushita K, et al. Lancet Diabetes Endocrinol. 2015; 3(7):514-525.
You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.
This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.
